| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 07/03/2002 | CN1356904A Compsns. comprising mixture of bioflavonols |
| 07/03/2002 | CN1356901A Pharmaceutical compsn. and process for its prepn. |
| 07/03/2002 | CN1356876A Compsns. containing creatine in suspension |
| 07/03/2002 | CN1356121A Composite health-care food and beverage for improving intelligence, taking care of brain health and delaying sanility and its preparing process |
| 07/03/2002 | CN1356117A Capsule 'Tangniaoshenkang' for treating diabetes |
| 07/03/2002 | CN1356115A Instant particles made of cordyceps and yak for making bone stronger |
| 07/03/2002 | CN1356112A Medicine for treating diabetes |
| 07/03/2002 | CN1356103A 抗疲劳组合物 Anti-fatigue composition |
| 07/03/2002 | CN1086943C Use of benzo-thiophene derivatives in preparing medicines for decreasing serum calcium levels |
| 07/02/2002 | US6414157 Compounds having high affinity for 5-ht1b and 5-ht1c serotonin receptor; antidepressants |
| 07/02/2002 | US6414153 1-phenylpydrrolidin-2-ones and -thiones and 1-(4-pyridyl)pydrrolidin-2-ones and -thiones which are useful in the treatment of inflammatory disease |
| 07/02/2002 | US6414149 Treating diabetes, treating or preventing diabetic complications |
| 07/02/2002 | US6414148 Produce antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals |
| 07/02/2002 | US6414144 Such as (2s)-(rel-7br,10ar)-2-methyl-1,2,3,4,8,9,10,10a-octahydro-7bh -cyclopenta(b)(1,4)diazepino(6,7,1-hi)indole; for treatment of obesity |
| 07/02/2002 | US6414126 C-aryl glucoside SGLT2 inhibitors and method |
| 07/02/2002 | US6414117 Compositions and methods for the treatment and diagnosis of immune disorders |
| 07/02/2002 | US6414029 Antidiabetic agents |
| 07/02/2002 | US6414012 Heterocyclic derivatives, method of production thereof and pharmaceutical use thereof |
| 07/02/2002 | US6414001 Ether and amide compounds preparation thereof composition containing same and use thereof as antidiadetics |
| 07/02/2002 | US6413991 Antidiabetic agents; dietetics |
| 07/02/2002 | US6413979 Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative |
| 07/02/2002 | US6413971 Antiproliferative, -carcinogenic, -tumor and -diabetic agents; binding to or modulating the human kinase insert-domain-containing receptor (kdr) or the murine fetal liver kinase 1 (flk-1) receptor; vasculogenesis; angiogenesis |
| 07/02/2002 | US6413965 Selective cox-2 and an aldose reductase inhibitor; neuropathy, nephropathy, retinopathy and cardiomyopathy; avoiding side effects such as gastric and renal toxicity |
| 07/02/2002 | US6413963 Alpha, beta-integrin inhibitors used in the treatment of multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease |
| 07/02/2002 | US6413936 Glycomimetics as selectin antagonists and pharmaceuticals having antiinflammatory activity |
| 07/02/2002 | US6413731 Methods of screening for compounds which bind to a human SNORF36A receptor |
| 07/02/2002 | US6413558 Compositions, kits, and methods for providing and maintaining energy and metal alertness |
| 07/02/2002 | CA2194984C 4-indole derivatives as serotonin agonists and antagonists |
| 07/02/2002 | CA2047283C Pyrazolopyridine compound and processes for preparation thereof |
| 06/28/2002 | CA2365642A1 Diacyglycerol acyltransferase (dgat) assay |
| 06/27/2002 | WO2002050289A1 Methods for the production of multimeric proteins, and related compositions |
| 06/27/2002 | WO2002050284A2 Oxidoreductases |
| 06/27/2002 | WO2002050279A2 Nucleic acid-associated proteins |
| 06/27/2002 | WO2002050257A2 Method for the production of polyfructans |
| 06/27/2002 | WO2002050221A1 A process for preparing vegetable oil fractions rich in non-tocolic, high-melting, unsaponifiable matter |
| 06/27/2002 | WO2002050090A1 Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| 06/27/2002 | WO2002050089A1 Method for purification of lactose |
| 06/27/2002 | WO2002050073A1 Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors |
| 06/27/2002 | WO2002050070A2 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists |
| 06/27/2002 | WO2002050068A1 Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| 06/27/2002 | WO2002050067A2 Pharmaceutical heterocyclic compounds |
| 06/27/2002 | WO2002050066A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050065A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050060A1 Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
| 06/27/2002 | WO2002050051A1 Chemical compounds |
| 06/27/2002 | WO2002050048A1 Thia- and oxazoles and their use as ppars activators |
| 06/27/2002 | WO2002050047A1 Substitued oxazoles and thiazoles as hppar alpha agonists |
| 06/27/2002 | WO2002050041A1 Dihydroindole and tetrahydroquinoline derivatives |
| 06/27/2002 | WO2002050036A1 Crystalline forms of cerivastatin sodium |
| 06/27/2002 | WO2002050033A1 Benzo(f) isoindol derivatives and their use as ep4 receptor ligands |
| 06/27/2002 | WO2002050032A1 Naphthalene derivatives which bind to the ep4 receptor |
| 06/27/2002 | WO2002050031A1 Indole derivatives |
| 06/27/2002 | WO2002050028A2 Substituted benzoindoles as spla2 inhibitors |
| 06/27/2002 | WO2002050027A1 Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
| 06/27/2002 | WO2002050021A1 Nitric oxide synthase inhibitor phosphate salt |
| 06/27/2002 | WO2002050019A2 Diamines as modulators of chemokine receptor activity |
| 06/27/2002 | WO2002050018A1 Dihydroceramide desaturase inhibitors. |
| 06/27/2002 | WO2002049993A2 High affinity small molecule c5a receptor modulators |
| 06/27/2002 | WO2002049664A1 Direct delivery of a gene product to the hypothalamus |
| 06/27/2002 | WO2002049661A1 Preventievs/remedies for diabetes and functional foods containing the same |
| 06/27/2002 | WO2002049657A1 Methods and compositions for reducing or preventing onset of milk fever |
| 06/27/2002 | WO2002049650A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
| 06/27/2002 | WO2002049649A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) |
| 06/27/2002 | WO2002049648A1 Heteroaryl urea neuropeptide y y5 receptor antagonists |
| 06/27/2002 | WO2002049646A1 Therapeutic combination of amlodipine and benazepril/benazeprilat |
| 06/27/2002 | WO2002049645A1 Therapeutic combination of amlodipine and benazepril |
| 06/27/2002 | WO2002049640A1 Triglyceride depressant composition |
| 06/27/2002 | WO2002049636A1 An antidiabetic composition of amino acids |
| 06/27/2002 | WO2002049634A2 Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect |
| 06/27/2002 | WO2002049626A2 The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity |
| 06/27/2002 | WO2002049575A2 Method and composition for the treatment of diabetic neuropathy |
| 06/27/2002 | WO2002030353A3 NF-λB INHIBITORS |
| 06/27/2002 | WO2002022602A3 Triazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002022592A3 Substituted urea neuropeptide y y5 receptor antagonists |
| 06/27/2002 | WO2002020822A3 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 06/27/2002 | WO2002020566A3 NOVEL MMP-2 DERIVATIVES FOR USE AS INHIBITORS OF INTEGRIN αVβ¿3? |
| 06/27/2002 | WO2002020501A3 Polyarylcarboxamides useful as lipid lowering agents |
| 06/27/2002 | WO2002018363A3 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors |
| 06/27/2002 | WO2002018323A3 Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors |
| 06/27/2002 | WO2002009704A3 Pharmaceutical composition for transdermal delivery of befloxatone |
| 06/27/2002 | WO2001098536A3 METHOD FOR ACTIVATING PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-$g(g) |
| 06/27/2002 | WO2001083746A3 Regulatory nucleic acid sequences of the abc1 gene |
| 06/27/2002 | WO2001078781A8 Methods for prevention and treatment of gastrointestinal disorders |
| 06/27/2002 | WO2001076584A3 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases |
| 06/27/2002 | WO2001073025A3 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains |
| 06/27/2002 | WO2001070978A3 Polypeptides and nucleic acids encoding same |
| 06/27/2002 | WO2001053257A3 Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them |
| 06/27/2002 | WO2001040182A3 Solid pharmaceutical preparation |
| 06/27/2002 | US20020082413 PGC-1, a novel brown fat PPARgamma coactivator |
| 06/27/2002 | US20020082412 Methods |
| 06/27/2002 | US20020082408 GSK3 polypeptides |
| 06/27/2002 | US20020082299 Administering a given dosage of creatine |
| 06/27/2002 | US20020082298 Non-insulin dependent diabetes mellitus, syndrome X, hyperlipidaemia, hypertension, hyperinsulinaemia, hypercholesterinaemia, hypertriglycerinaemia, impaired glucose tolerance and related obesity |
| 06/27/2002 | US20020082292 Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma |
| 06/27/2002 | US20020082278 Use to treat allergy, nasal congestion, inflammatory and central nervous system-related diseases |
| 06/27/2002 | US20020082272 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 06/27/2002 | US20020082261 Prophylactic or therapeutic agents for diseases haivng vascular dysfunction associated with insulin resistance |
| 06/27/2002 | US20020082260 Isoindolin-1-one-substituted propionamide glucokinase activators which increase insulin secretion in the treatment of type II diabetes |
| 06/27/2002 | US20020082258 Novel antitobesity and hypocholesterolemic compounds lower total cholesterol; increase high density lipoprotein (HDL) and decrease low denstiy lipoprotein |
| 06/27/2002 | US20020082257 Elevates ATP binding cassette transporter 1 expression thereby increasing efflux of cholesterol from cells by active transfer into high density lipoproteins |